v3.26.1
Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue:            
Collaboration and license revenue $ 0   $ 0   $ 0 $ 400
Grant revenue 0   298   78 998
Total revenues 0   298   78 1,398
Operating expenses:            
Research and development 20,431   14,869   39,894 29,543
General and administrative 8,724   7,240   15,838 15,555
Net income (loss) 15,769 $ (39,182) 15,886 $ (17,710) (23,413) (1,824)
Operating Segment            
Revenue:            
Collaboration and license revenue 0   0   0 400
Grant revenue 0   298   78 998
Total revenues 0   298   78 1,398
Operating expenses:            
General and administrative 8,724   7,240   15,838 15,555
Other (income) expense, net (44,924)   (37,697)   (32,241) 45,098
Net income (loss) 15,769   15,886   (23,413) (1,824)
Operating Segment | Descartes-08 for MG            
Operating expenses:            
Research and development 12,465   5,035   24,600 12,071
Operating Segment | Descartes-08 for dermatomyositis            
Operating expenses:            
Research and development 236   0   463 0
Operating Segment | Early stage programs            
Operating expenses:            
Research and development 971   1,715   1,326 2,705
Operating Segment | Research and development employee expenses            
Operating expenses:            
Research and development 4,027   4,254   7,855 7,956
Operating Segment | Research and development stock-based compensation expense            
Operating expenses:            
Research and development 614   1,810   1,563 3,085
Operating Segment | Research and development facilities and other expenses            
Operating expenses:            
Research and development $ 2,118   $ 2,055   $ 4,087 $ 3,726